Back

SGLT-2 inhibitors in T2DM management: current position & future promise.

28 August 2016 (13:05 - 13:25)
Organised by:
Congress Presentation Part of: SGLT2 inhibition, diabetes and CVD: where does this fit in CV risk management? Diabetes management ESC Premium Access ESC Congress 2016

About the speaker

Photo
Professor Silvio Inzucchi

New Haven (United States of America)

4 More presentations in this session

Presentation thumbnail
Introduction - SGLT2 inhibition, diabetes and CVD: where does this fit in CV risk management?
Doctor D. Fitchett (Toronto, CA)
Presentation thumbnail
Challenging CV Risk in diabetes: ready for a new approach?
Professor J. Deanfield (London, GB)
Presentation thumbnail
Heart failure & diabetes: SGLT2 inhibition, a paradigm shift?
Professor J. McMurray (Glasgow, GB)
Presentation thumbnail
Panel discussion - SGLT2 inhibition, diabetes and CVD: where does this fit in CV risk management?
Doctor D. Fitchett (Toronto, CA) Professor J. McMurray (Glasgow, GB)

Access the full session

Session thumbnail
SGLT2 inhibition, diabetes and CVD: where does this fit in CV risk management?

The Event

Event poster

ESC Congress 2016

28 August 2016 13:05 CET
You may be interested in
thumbnail
Congress Presentation
Sodium-glucose cotransporter 2 inhibitors in patients with transthyretin amyloid cardiomyopathy - results from a patient series
20 May 2023
thumbnail
Congress Session
Real-world experience from an MDT cardiometabolic clinic
23 June 2023
thumbnail
Webinar
Clinical trials and highlights from ACC 2024
10 April 2024
thumbnail
Congress Presentation
Patient vascular model reveals anti-inflammatory effects of SGLT2 inhibitor by modulating endothelial-T cell crosstalk
31 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources